Pipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continues Gross margin increases to 80.3%; balance sheet remains strong GAITHERSBURG, Md., Aug. 15, 2023 /PRNewswire/ — YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”), a…